Loading resource…

Department of Population Health Sciences, School of Life Course & Population Sciences, King’s College London
Incretin-based therapies, including GLP-1 receptor agonists, have significantly impacted obesity management, leading to weight loss and improvements in cardiometabolic health. However, these therapies can also pose nutritional and psychological risks, such as reduced appetite and gastrointestinal side effects. This document provides recommendations on dietary management, protein intake, and exercise to support individuals during treatment, emphasizing the need for individualized dietary advice and multidisciplinary care.
No account needed